<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893371</url>
  </required_header>
  <id_info>
    <org_study_id>16-243</org_study_id>
    <secondary_id>CER-1507-31607</secondary_id>
    <nct_id>NCT02893371</nct_id>
  </id_info>
  <brief_title>Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies</brief_title>
  <official_title>Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montana State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Alliance on Mental Illness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CGStat LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Risk Benefit Statistics LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this retrospective observational study is to compare commonly prescribed
      bipolar disorder medications for their impact on: (1) all-cause mortality; (2)
      hospitalization; (3) mood episodes; (4) suicide attempts and self-harm; and (5) risk of
      drug-induced adverse effects such as kidney disease/failure and metabolic syndrome. In
      addition, the investigators will examine heterogeneity of treatment effect by co-morbidity
      within pediatric, adult, and elderly sub-populations. Patient focus groups are convened to
      elicit additional questions and provide feedback on results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Funded by PCORI, the objective of this retrospective observational study is to perform
      several safety and effectiveness comparisons on commonly prescribed bipolar disorder
      medications, engaging patient focus groups in generating additional questions and
      interpreting results.

      The study will be a retrospective cohort study conducted with administrative claims data from
      the Truven MarketScan Commerical Claims and Encounters and Medicare database from 2010-2016.

      The database contains approximately 100 million patients within the US population in every
      state and nearly every county in the nation, across all ages, ethnicities and socioeconomic
      categories, including privately insured, and Medicare patients. The study will focus on
      approximately 1.3 million patients with two or more diagnoses of bipolar disorder in the
      claims records according to ICD-9 and/or ICD-10 coding.

      The treatments that will be compared are lithium carbonate; first generation antipsychotics:
      haloperidol and perphenazine; second generation antipsychotics: clozapine, risperidone,
      olanzapine, aripiprazole, quetiapine, ziprasidone, asenapine, lurasidone, and paliperidone;
      mood stabilizing anticonvulsants: valproate, lamotrigine, carbamazepine, and oxcarbazepine;
      antidepressants: mirtazapine, bupropion, desvenlafaxine, duloxetine, venlafaxine, citalopram,
      escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vilazodone, and doxepin.

      The investigators will perform cross-sectional and survival based analysis using regression,
      propensity scoring, and local control to perform bias-corrected comparisons of the above
      treatments for for their impact on: (1) all-cause mortality; (2) risk of hospitalization; (3)
      frequency of manic and depressive mood episodes; (4) risk of suicide attempts and self-harm;
      and (5) risk of drug-induced adverse effects such as kidney disease/failure and metabolic
      syndrome. In addition, the investigators will examine heterogeneity of treatment effect by
      co-morbidity within pediatric, adult, and elderly sub-populations.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of hospitalization</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess the risk of rehospitalization within 30-days after hospitalization for a mood episode. For each treatment, assess the cumulative incidence of hospitalization for a mood episode any time after commencing treatment, accounting for the competing risk of ending treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of suicide and self-harm</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess the cumulative risk of a second suicide or self-harm event after diagnosis of a first event, accounting for the competing risk of ending treatment. Self-harm includes injuries of unknown intent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of manic and depressive mood episodes</measure>
    <time_frame>0-7 years</time_frame>
    <description>Assess the number of mood episodes per days on treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess time to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney disease</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess time to first instance of renal condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic syndrome</measure>
    <time_frame>0-7 years</time_frame>
    <description>For each treatment, assess time to diagnosis of metabolic syndrome.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1300000</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Lithobid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Depakote</other_name>
    <other_name>Valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Trileptal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Equetro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine / Olanzapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Symbyax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Haldol Decanoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perphenazine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Trilafon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Clozaril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Saphris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Latuda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Invega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Remeron</other_name>
    <other_name>Remeronsoltab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Zyban</other_name>
    <other_name>Aplenzin</other_name>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Pristiq</other_name>
    <other_name>Desfax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Cymbalta</other_name>
    <other_name>Irenka</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Effexor XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Celexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Prozac</other_name>
    <other_name>Sarafem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Faverin</other_name>
    <other_name>Fevarin</other_name>
    <other_name>Floxyfral</other_name>
    <other_name>Dumyrox</other_name>
    <other_name>Luvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Paxil</other_name>
    <other_name>Seroxat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilazodone</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Viibryd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxepin</intervention_name>
    <description>Exposure to all dosages and delivery forms.</description>
    <other_name>Sinequan</other_name>
    <other_name>Silenor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of individuals with bipolar disorder enrolled with private
        insurers or with Medicare across the United States, as captured in the Truven Health
        Analytics MarketScan databases. The time period of data coverage is 2003-2015.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Two or more instances of bipolar disorder diagnoses within administrative claims
             records

        Exclusion Criteria:

          -  Patients with less than 1 year of history in the database
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe G Lambert, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christophe G Lambert</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pcori.org/research-results/2016/longitudinal-comparative-effectiveness-bipolar-disorder-therapies</url>
    <description>Announcement of PCORI project award.</description>
  </link>
  <results_reference>
    <citation>Nestsiarovich A, Hurwitz NG, Nelson SJ, Crisanti AS, Kerner B, Kuntz MJ, Smith AN, Volesky E, Schroeter QL, DeShaw JL, Young SS, Obenchain RL, Krall RL, Jordan K, Fawcett J, Tohen M, Perkins DJ, Lambert CG. Systemic challenges in bipolar disorder management: A patient-centered approach. Bipolar Disord. 2017 Dec;19(8):676-688. doi: 10.1111/bdi.12547. Epub 2017 Sep 13.</citation>
    <PMID>28901625</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Christophe Gerard Lambert</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Asenapine</mesh_term>
    <mesh_term>Perphenazine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
    <mesh_term>Vilazodone Hydrochloride</mesh_term>
    <mesh_term>Doxepin</mesh_term>
    <mesh_term>Oxcarbazepine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This retrospective observational study makes use of MarketScan individual level patient data from Truven Health Analytics. The license terms for data access prohibit public dissemination of individual level patient data. The investigators will, however, make openly available the queries and analytic procedures required to reproduce the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

